587 related articles for article (PubMed ID: 16954373)
41. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
[TBL] [Abstract][Full Text] [Related]
42. Evidence of endogenous mu opioid receptor regulation by epigenetic control of the promoters.
Hwang CK; Song KY; Kim CS; Choi HS; Guo XH; Law PY; Wei LN; Loh HH
Mol Cell Biol; 2007 Jul; 27(13):4720-36. PubMed ID: 17452465
[TBL] [Abstract][Full Text] [Related]
43. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
[TBL] [Abstract][Full Text] [Related]
44. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
Xu J; Huo D; Chen Y; Nwachukwu C; Collins C; Rowell J; Slamon DJ; Olopade OI
Breast Cancer Res Treat; 2010 Apr; 120(3):593-601. PubMed ID: 19466541
[TBL] [Abstract][Full Text] [Related]
45. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation.
Wu Y; Alvarez M; Slamon DJ; Koeffler P; Vadgama JV
BMC Cancer; 2010 Feb; 10():32. PubMed ID: 20132554
[TBL] [Abstract][Full Text] [Related]
46. Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL).
Kn H; Bassal S; Tikellis C; El-Osta A
Cancer Biol Ther; 2004 Oct; 3(10):989-94. PubMed ID: 15467427
[TBL] [Abstract][Full Text] [Related]
47. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter.
Wu LP; Wang X; Li L; Zhao Y; Lu S; Yu Y; Zhou W; Liu X; Yang J; Zheng Z; Zhang H; Feng J; Yang Y; Wang H; Zhu WG
Mol Cell Biol; 2008 May; 28(10):3219-35. PubMed ID: 18332107
[TBL] [Abstract][Full Text] [Related]
48. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
Lee SH; Kim J; Kim WH; Lee YM
Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
[TBL] [Abstract][Full Text] [Related]
49. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
Kim TY; Jong HS; Song SH; Dimtchev A; Jeong SJ; Lee JW; Kim TY; Kim NK; Jung M; Bang YJ
Oncogene; 2003 Jun; 22(25):3943-51. PubMed ID: 12813468
[TBL] [Abstract][Full Text] [Related]
50. UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer.
Jin W; Chen L; Chen Y; Xu SG; Di GH; Yin WJ; Wu J; Shao ZM
Breast Cancer Res Treat; 2010 Sep; 123(2):359-73. PubMed ID: 19943104
[TBL] [Abstract][Full Text] [Related]
51. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
52. Differential regulation of the alcohol dehydrogenase 1B (ADH1B) and ADH1C genes by DNA methylation and histone deacetylation.
Dannenberg LO; Chen HJ; Tian H; Edenberg HJ
Alcohol Clin Exp Res; 2006 Jun; 30(6):928-37. PubMed ID: 16737450
[TBL] [Abstract][Full Text] [Related]
53. Epigenetic inactivation of Betaig-h3 gene in human cancer cells.
Shao G; Berenguer J; Borczuk AC; Powell CA; Hei TK; Zhao Y
Cancer Res; 2006 May; 66(9):4566-73. PubMed ID: 16651406
[TBL] [Abstract][Full Text] [Related]
54. [Expression of neprilysin gene is associated with methylation and histone modification on promoter in mouse neuroblastoma Neuro-2a cells].
Deng Y; Lu X; Liu L; Li T; Zhang Y; Guo X; Yu G
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):810-3. PubMed ID: 25108432
[TBL] [Abstract][Full Text] [Related]
55. hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications.
Xiong Y; Dowdy SC; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2006 Oct; 103(1):321-8. PubMed ID: 16701802
[TBL] [Abstract][Full Text] [Related]
56. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation.
El-Osta A; Kantharidis P; Zalcberg JR; Wolffe AP
Mol Cell Biol; 2002 Mar; 22(6):1844-57. PubMed ID: 11865062
[TBL] [Abstract][Full Text] [Related]
57. [Two CpG-islands of SEMA3B gene: methylation in clear cell renal cell carcinoma].
Loginov VI; Khodyrev DS; Pronina IV; Maliukova AV; Kazubskaia TP; Ermilova VD; Gar'kavtseva RF; Zabarovskiĭ ER; Braga EA
Mol Biol (Mosk); 2009; 43(6):1088-92. PubMed ID: 20088387
[TBL] [Abstract][Full Text] [Related]
58. Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells.
Nakano H; Nakamura Y; Soda H; Kamikatahira M; Uchida K; Takasu M; Kitazaki T; Yamaguchi H; Nakatomi K; Yanagihara K; Kohno S; Tsukamoto K
Cancer; 2008 Mar; 112(5):1122-30. PubMed ID: 18219662
[TBL] [Abstract][Full Text] [Related]
59. Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
Ibanez de Caceres I; Dulaimi E; Hoffman AM; Al-Saleem T; Uzzo RG; Cairns P
Cancer Res; 2006 May; 66(10):5021-8. PubMed ID: 16707423
[TBL] [Abstract][Full Text] [Related]
60. PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation.
Venza I; Visalli M; Fortunato C; Ruggeri M; Ratone S; Caffo M; Caruso G; Alafaci C; Tomasello F; Teti D; Venza M
Epigenetics; 2012 Nov; 7(11):1315-30. PubMed ID: 23051921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
